Opioid use disorder (OUD) is a chronic brain disease that stems from prolonged use of opioids, encompassing both prescription painkillers and illegal opioids. The development of opioid use disorder is influenced by a combination of genetic, environmental, and behavioral factors.
The primary medications for treating opioid use disorder (OUD) include buprenorphine, naltrexone, and methadone. Buprenorphine, classified as an opioid, is utilized in the management of opioid use disorder to mitigate cravings and alleviate withdrawal symptoms associated with opioid dependence. This medication is administered through oral and parenteral routes and is applicable across various age groups, including those aged 19 to 40, 41 to 60, and 61 and over. Distribution channels for buprenorphine include hospital pharmacies, retail pharmacies and stores, as well as online pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The opioid use disorder (OUD) research report is one of a series of new reports from The Business Research Company that provides opioid use disorder (OUD) market statistics, including the opioid use disorder (OUD) industry's global market size, regional shares, competitors with opioid use disorder (OUD) market share, detailed opioid use disorder (OUD) market segments, market trends and opportunities, and any further data you may need to thrive in the opioid use disorder (OUD) industry. This opioid use disorder (OUD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The opioid use disorder (oud) market size has grown rapidly in recent years. It will grow from $3.96 billion in 2024 to $4.37 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to increased prescription rates, pain management practices, drug marketing, stigmatization of addiction.
The opioid use disorder (oud) market size is expected to see rapid growth in the next few years. It will grow to $6.91 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to regulatory interventions, focus on alternative pain management, expansion of treatment access, public health initiatives,. Major trends in the forecast period include technological innovations in treatment, individualized treatment approaches, integrated care models, community-based support programs, early intervention and prevention.
The forecast of 12.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of long-acting buprenorphine implants by inflating prices of sustained-release addiction therapies developed in Australia and Canada, resulting in higher relapse rates and elevated substance abuse treatment program costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing incidence of opioid addiction is anticipated to drive the growth of the opioid use disorder (OUD) market in the future. Opioid addiction is a medical condition defined by compulsive and chronic use of opioids, resulting in harmful effects on the body. Opioids can create feelings of euphoria and provide pain relief; however, their continued use can lead to the development of tolerance, necessitating higher doses to achieve the same effects, which may ultimately result in opioid use disorder. For example, in March 2024, the Centers for Disease Control and Prevention, a US-based public health agency, reported a 4.1% increase in the rate of synthetic opioid drug overdoses, rising from 21.8 to 22.7 between 2021 and 2022. Therefore, the rising number of opioid addiction cases is driving the growth of the opioid use disorder (OUD) market.
The upsurge in the prevalence of chronic diseases is anticipated to propel the expansion of the opioid use disorder (OUD) market. Chronic diseases persist for a year or longer, demanding continuous medical attention and often limiting daily activities. Many chronic conditions, such as severe pain associated with cancer, arthritis, or other long-term ailments, frequently necessitate the use of opioid medications for effective pain management. For instance, projections from the National Centre for Biotechnology Information (NCBI) in January 2023 estimated a staggering 99.5% increase by the year 2050 in the number of individuals aged 50 years and older afflicted with at least one chronic illness, rising from 71.522 million in 2020 to 142.66 million. Thus, the surge in chronic disease prevalence is a driving force behind the growth of the opioid use disorder (OUD) market.
Product innovation stands out as a significant and increasingly favored trend in the opioid use disorder (OUD) market. Major companies operating within this sector are actively engaged in developing innovative products to maintain their market standing. An illustrative instance occurred in May 2023 when the U.S. Food and Drug Administration, a federal agency in the United States, granted approval for Brixadi (buprenorphine) extended-release injection to address moderate to severe cases of opioid use disorder (OUD). Brixadi is available in two dosage forms such as a weekly injection designed for patients commencing treatment with a single dose of transmucosal buprenorphine or those presently using the medication, and a monthly version tailored for individuals already receiving this treatment.
Prominent entities in the opioid use disorder (OUD) market are focused on forging strategic alliances to bolster their market position. Strategic alliances, taking diverse forms, aim to yield mutual benefits and fortify the market positions of the participating companies. An exemplar of this strategy occurred in March 2023, as Harm Reduction Therapeutics, a non-profit pharmaceutical company based in the United States, partnered with Catalent, Inc., a company specializing in developing and delivering advanced treatments globally. Within this collaboration, Catalent, Inc. will undertake the manufacturing of RiVive (3.0 mg), a naloxone nasal spray intended for harm reduction therapy, facilitating emergency treatment for known or suspected opioid overdose cases. This alliance was driven by the urgent need to address the ongoing opioid epidemic on a national scale. The goal behind developing an over-the-counter naloxone solution is to significantly broaden access, making naloxone more readily available to save lives imperiled by opioid overdoses.
In March 2023, the US-based pharmaceutical company Indivior plc successfully completed the acquisition of Opiant Pharmaceuticals Inc. for a total of $145 million. This strategic move is poised to enhance Indivior's product portfolio in the addiction treatment sector, fortifying its position in the market. Opiant Pharmaceuticals Inc., the acquired entity, is also based in the United States and specializes in the development of pharmaceuticals targeted at addressing opioid overdose, acute cannabinoid overdose, and opioid use disorder.
Major companies operating in the opioid use disorder (OUD) market include Pfizer Inc., Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Chiesi Pharmaceuticals S.p.A., Hikma Pharmaceuticals Plc., Mallinckrodt Pharmaceuticals, Indivior Plc., Purdue Pharma L.P, Alkermes Inc., Collegium Pharmaceutical Inc., Vanda Pharmaceuticals Inc., Camurus AB, Tris Pharma Inc., Mylan NV., Orexo US Inc., Zogenix Inc., Rhodes Pharmaceuticals L.P., Omeros Corporation, Braeburn Pharmaceuticals Inc., Adapt Pharma Inc., Titan Pharmaceuticals Inc., BioDelivery Sciences International Inc., AcelRx Pharmaceuticals Inc., KemPharm Inc.
North America was the largest region in the opioid use disorder (OUD) market in 2024. The regions covered in the opioid use disorder (oud) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the opioid use disorder (oud) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The opioid use disorder (OUD) market consists of sales of bunavail, sublocade, suboxone, and zubsolv. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Opioid Use Disorder (OUD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on opioid use disorder (oud) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for opioid use disorder (oud) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The opioid use disorder (oud) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Type: Buprenorphine; Naltrexone; Methadone
- 2) By Route of Administration: Oral; Parenteral
- 3) By Age Group: 19 To 40; 41 To 60; 61 And Over
- 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies And Stores; Online Pharmacies
- Subsegments:
- 1) By Buprenorphine: Suboxone; Buprenorphine Tablets; Buprenorphine Film
- 2) By Naltrexone: Naltrexone Tablets; Vivitrol
- 3) By Methadone: Methadone Tablets; Methadone Oral Solution
- Companies Mentioned: Pfizer Inc.; Novartis AG; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Chiesi Pharmaceuticals S.p.A.; Hikma Pharmaceuticals Plc.; Mallinckrodt Pharmaceuticals; Indivior Plc.; Purdue Pharma L.P; Alkermes Inc.; Collegium Pharmaceutical Inc.; Vanda Pharmaceuticals Inc.; Camurus AB; Tris Pharma Inc.; Mylan NV.; Orexo US Inc.; Zogenix Inc.; Rhodes Pharmaceuticals L.P.; Omeros Corporation; Braeburn Pharmaceuticals Inc.; Adapt Pharma Inc.; Titan Pharmaceuticals Inc.; BioDelivery Sciences International Inc.; AcelRx Pharmaceuticals Inc.; KemPharm Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Opioid Use Disorder (OUD) Market Characteristics
3. Opioid Use Disorder (OUD) Market Trends And Strategies
4. Opioid Use Disorder (OUD) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Opioid Use Disorder (OUD) Growth Analysis And Strategic Analysis Framework
- 5.1. Global Opioid Use Disorder (OUD) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Opioid Use Disorder (OUD) Market Growth Rate Analysis
- 5.4. Global Opioid Use Disorder (OUD) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Opioid Use Disorder (OUD) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Opioid Use Disorder (OUD) Total Addressable Market (TAM)
6. Opioid Use Disorder (OUD) Market Segmentation
- 6.1. Global Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Buprenorphine
- Naltrexone
- Methadone
- 6.2. Global Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- 6.3. Global Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19 To 40
- 41 To 60
- 61 And Over
- 6.4. Global Opioid Use Disorder (OUD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies And Stores
- Online Pharmacies
- 6.5. Global Opioid Use Disorder (OUD) Market, Sub-Segmentation Of Buprenorphine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Suboxone
- Buprenorphine Tablets
- Buprenorphine Film
- 6.6. Global Opioid Use Disorder (OUD) Market, Sub-Segmentation Of Naltrexone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Naltrexone Tablets
- Vivitrol
- 6.7. Global Opioid Use Disorder (OUD) Market, Sub-Segmentation Of Methadone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Methadone Tablets
- Methadone Oral Solution
7. Opioid Use Disorder (OUD) Market Regional And Country Analysis
- 7.1. Global Opioid Use Disorder (OUD) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Opioid Use Disorder (OUD) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Opioid Use Disorder (OUD) Market
- 8.1. Asia-Pacific Opioid Use Disorder (OUD) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Opioid Use Disorder (OUD) Market
- 9.1. China Opioid Use Disorder (OUD) Market Overview
- 9.2. China Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Opioid Use Disorder (OUD) Market
- 10.1. India Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Opioid Use Disorder (OUD) Market
- 11.1. Japan Opioid Use Disorder (OUD) Market Overview
- 11.2. Japan Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Opioid Use Disorder (OUD) Market
- 12.1. Australia Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Opioid Use Disorder (OUD) Market
- 13.1. Indonesia Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Opioid Use Disorder (OUD) Market
- 14.1. South Korea Opioid Use Disorder (OUD) Market Overview
- 14.2. South Korea Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Opioid Use Disorder (OUD) Market
- 15.1. Western Europe Opioid Use Disorder (OUD) Market Overview
- 15.2. Western Europe Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Opioid Use Disorder (OUD) Market
- 16.1. UK Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Opioid Use Disorder (OUD) Market
- 17.1. Germany Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Opioid Use Disorder (OUD) Market
- 18.1. France Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Opioid Use Disorder (OUD) Market
- 19.1. Italy Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Opioid Use Disorder (OUD) Market
- 20.1. Spain Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Opioid Use Disorder (OUD) Market
- 21.1. Eastern Europe Opioid Use Disorder (OUD) Market Overview
- 21.2. Eastern Europe Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Opioid Use Disorder (OUD) Market
- 22.1. Russia Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Opioid Use Disorder (OUD) Market
- 23.1. North America Opioid Use Disorder (OUD) Market Overview
- 23.2. North America Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Opioid Use Disorder (OUD) Market
- 24.1. USA Opioid Use Disorder (OUD) Market Overview
- 24.2. USA Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Opioid Use Disorder (OUD) Market
- 25.1. Canada Opioid Use Disorder (OUD) Market Overview
- 25.2. Canada Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Opioid Use Disorder (OUD) Market
- 26.1. South America Opioid Use Disorder (OUD) Market Overview
- 26.2. South America Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Opioid Use Disorder (OUD) Market
- 27.1. Brazil Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Opioid Use Disorder (OUD) Market
- 28.1. Middle East Opioid Use Disorder (OUD) Market Overview
- 28.2. Middle East Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Opioid Use Disorder (OUD) Market
- 29.1. Africa Opioid Use Disorder (OUD) Market Overview
- 29.2. Africa Opioid Use Disorder (OUD) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Opioid Use Disorder (OUD) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Opioid Use Disorder (OUD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Opioid Use Disorder (OUD) Market Competitive Landscape And Company Profiles
- 30.1. Opioid Use Disorder (OUD) Market Competitive Landscape
- 30.2. Opioid Use Disorder (OUD) Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Chiesi Pharmaceuticals S.p.A. Overview, Products and Services, Strategy and Financial Analysis
31. Opioid Use Disorder (OUD) Market Other Major And Innovative Companies
- 31.1. Hikma Pharmaceuticals Plc.
- 31.2. Mallinckrodt Pharmaceuticals
- 31.3. Indivior Plc.
- 31.4. Purdue Pharma L.P
- 31.5. Alkermes Inc.
- 31.6. Collegium Pharmaceutical Inc.
- 31.7. Vanda Pharmaceuticals Inc.
- 31.8. Camurus AB
- 31.9. Tris Pharma Inc.
- 31.10. Mylan NV.
- 31.11. Orexo US Inc.
- 31.12. Zogenix Inc.
- 31.13. Rhodes Pharmaceuticals L.P.
- 31.14. Omeros Corporation
- 31.15. Braeburn Pharmaceuticals Inc.
32. Global Opioid Use Disorder (OUD) Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Opioid Use Disorder (OUD) Market
34. Recent Developments In The Opioid Use Disorder (OUD) Market
35. Opioid Use Disorder (OUD) Market High Potential Countries, Segments and Strategies
- 35.1 Opioid Use Disorder (OUD) Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Opioid Use Disorder (OUD) Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Opioid Use Disorder (OUD) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
